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Abstract.
Background: Decreased concentrations of amyloid- 1-42 (A42) in cerebrospinal fluid (CSF) and increased retention of
A tracers in the brain on positron emission tomography (PET) are considered the earliest biomarkers of Alzheimer’s disease
(AD). However, a proportion of cases show discrepancies between the results of the two biomarker modalities which may
reflect inter-individual differences in A metabolism. The CSF A42/40 ratio seems to be a more accurate biomarker of
clinical AD than CSF A42 alone.
Objective: We tested whether CSF A42 alone or the A42/40 ratio corresponds better with amyloid PET status and analyzed
the distribution of cases with discordant CSF-PET results.
Methods: CSF obtained from a mixed cohort (n = 200) of cognitively normal and abnormal research participants who had
undergone amyloid PET within 12 months (n = 150 PET-negative, n = 50 PET-positive according to a previously published
cut-off) was assayed for A42 and A40 using two recently developed immunoassays. Optimal CSF cut-offs for amyloid
positivity were calculated, and concordance was tested by comparison of the areas under receiver operating characteristic
(ROC) curves (AUC) and McNemar’s test for paired proportions.
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Results: CSF A42/40 corresponded better than A42 with PET results, with a larger proportion of concordant cases (89.4%
versus 74.9%, respectively, p < 0.0001) and a larger AUC (0.936 versus 0.814, respectively, p < 0.0001) associated with the
ratio. For both CSF biomarkers, the percentage of CSF-abnormal/PET-normal cases was larger than that of CSF-normal/PET-
abnormal cases.
Conclusion: The CSF A42/40 ratio is superior to A42 alone as a marker of amyloid-positivity by PET. We hypothesize that
this increase in performance reflects the ratio compensating for general between-individual variations in CSF total A.
Keywords: Alzheimer’s disease, amyloid-, biomarker, cerebrospinal fluid, positron emission tomography
INTRODUCTION
Reduced concentrations of amyloid- (A) 1-42
in the cerebrospinal fluid (CSF) are associated with
increased retention of A tracers in the brain via
positron emission tomography (PET) [1–5] and both
are considered the earliest biomarkers of Alzheimer’s
disease (AD) [6–10]. However, several published
studies show that results of the two measures are
discordant in a proportion of individuals in the
cohorts evaluated to date, most notably as CSF A42-
abnormal/amyloid PET-normal (reviewed in [11]).
Such discordance may reflect assay methodological
variability and/or imprecision, or these biomarker
modalities may reflect partly different pathophysio-
logic events [12].
Results from several groups demonstrate that nor-
malization of the CSF A42 concentration to the level
of total A peptides (or the most abundant isoform,
A 1-40 [A40]) in the CSF by means of an A42/40
ratio improves the accuracy of clinical AD diag-
nosis [13–17] by “controlling for” inter-individual
differences in overall levels of CSF A. This led us
to hypothesize that the CSF concentration of A42
depends not only on the pathophysiological status
of a given individual, hence suggesting the presence
or absence of AD pathology, but also on the total
amount of A peptides in the CSF, i.e., the total pro-
duction of A in the brain. At least two additional
arguments, derived from experience regarding pre-
analytical sample handling and data interpretation,
further support the application of the A42/40 ratio
for AD diagnostic purposes: (a) A42/40 is less prone
to the error of misinterpretation when inappropriate
test tubes to collect CSF are used [18] (likely due to
the similar amount of absorption of both A species);
and (b) in two studies that applied the A42/40 ratio
measured with the same ELISA assays to predict AD
in mild cognitive impairment (MCI) subjects [15]
or in early symptomatic AD [19], virtually identical
A42/40 cut-offs were obtained despite differences in
absolute A42 concentrations.
Considering these data, we hypothesized that the
CSF A42/40 ratio might reflect amyloid PET sta-
tus (positive versus negative) better than the A42
concentration alone. To test this hypothesis, we used
dichotomized PET results to calculate the optimal
cut-offs for A42 concentrations and A42/40 ratios
measured with two novel, recently validated ELISAs
[14], and then compared the concordance of each
of the two CSF biomarkers with the results of the
amyloid PET. We also compared the distribution of
the discordant results, i.e., the percentage of cases
with pathologic CSF findings and normal PET results
versus the percentage with normal CSF and patho-
logic PET results. We proposed that the results from
these analyses might provide insight into the possible
mechanism(s) for the observed known discordance
between amyloid imaging and levels of CSF A42




All procedures were approved by the Institutional
Review Board and the Washington University Human
Research Protection Office, and written informed
consent was obtained from each participant. Partici-
pants were community-dwelling volunteers enrolled
in studies of normal aging and dementia at the Knight
Alzheimer’s Disease Research Center (ADRC) at
Washington University in St. Louis. Participants were
45–83 years of age at baseline and had no neuro-
logical, psychiatric or systemic medical illness that
might compromise longitudinal study participation,
nor medical contraindication to lumbar puncture (LP)
or PET. All participants underwent cognitive assess-
ments (including the Mini-Mental State Examination
(MMSE) [20]), neurological evaluations and clini-
cal assessments that included the Clinical Dementia
Rating (CDR) [21].
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To be included in the present analysis, baseline
clinical and cognitive assessment, and LP and amy-
loid PET (via Pittsburgh Compound B, PiB) within 12
months of each other had to be available (mean ± SD,
67 ± 78 days). Two-hundred CSF samples were
selected a priori based on cortical amyloid load via
PET (25% amyloid PET-positive and 75% amyloid
PET-negative, see below), independent of and blinded
to participant demographics and clinical status. Given
published reports of greater CSF-PET discordance
in amyloid PET-negative individuals, greater num-
bers of amyloid-negative participant samples were
evaluated so to enrich for possible and more com-
mon discordant (PiB-negative/A42-positive) cases.
APOEgenotype was obtained from the Knight ADRC
Genetics Core [22].
CSF collection, processing, and analysis
CSF was collected and processed according to
standardized protocols. Samples (20–30 mL) were
collected using LP procedures (22 G × 3 1/2 inch
atraumatic Sprotte spinal needle, Pajunk, #001151-
30 C) via gravity drip into a 50 mL conical
polypropylene tube (Corning #430829) at 8 : 00am
after overnight fasting, gently inverted to avoid pos-
sible rostro-caudal gradient effects and immediately
put on wet ice. Within 1 h of collection, samples
were briefly centrifuged at low speed (2000× g,
5 min at 4◦C) to pellet any cellular debris. All but
the bottom 500L was transferred to a new 50 mL
polypropylene tube, aliquoted (500L) into sterile
2 mL polypropylene screw-cap tubes with O-rings
(Corning #430915), and immediately frozen at –80◦C
until analysis. The interval between sample collection
and batch analysis varied from 1–9 years, with equal
representation of storage intervals among the differ-
ent amyloid PET groups (PiB+ versus PiB-). Samples
underwent a single freeze-thaw cycle prior to assay,
were thawed on wet ice (∼3 h) followed by vortexing
prior to blinded analysis, and were run in duplicate.
A42 and A40 concentrations were measured with
immunoassays from IBL International (Hamburg,
Germany) according to the manufacturer’s proto-
cols. To be included in the statistical analyses, the
results had to pass quality control (QC) criteria con-
sistent with the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) study [23], including coefficients of
variability (CV) of duplicates ≤25% and the results of
the kit’s run validation samples (“kit controls”) within
the acceptable range as defined by the manufacturer.
Samples also had data available for A42, Tau, and
pTau181 using INNOTEST ELISA kits (Fujirebio,
Ghent, Belgium).
In vivo amyloid imaging
Participants received a single intravenous bolus
injection of 11[C] PiB (between 4.7 and 19.0 mCi).
PET imaging [24] was conducted with a Siemens
962 HR+ ECAT PET or Biograph 40 scanner
(Siemens/CTI, Knoxville KY), and magnetic reso-
nance imaging (MRI) using MPRAGE T1-weighted
images (1 mm × 1 mm × 1.25 mm) was obtained for
anatomic reference as described previously [25, 26].
Participants underwent a 60-min dynamic scan with
11[C] PiB, and PET data was processed using regions
of interest (ROIs) derived from structural MRIs using
Freesurfer [25, 26]. Regional time-activity curves
were extracted for each ROI, and binding poten-
tials were calculated using Logan graphical analysis
[27] with cerebellar gray matter as the reference
region. The mean cortical binding potential (MCBP)
was calculated based on a set of selected cortical
regions known to have high levels of deposition in AD
[28], including precuneus, rostral middle frontal cor-
tex, superior frontal cortex, superior temporal cortex,
middle temporal cortex, lateral orbitofrontal cortex,
and medial orbitofrontal cortex [25]. A MCBP cutoff
of >0.18 for positivity was chosen to be consistent
with prior studies [9, 28–30].
Statistical analyses
Sample size was calculated with the nega-
tive/positive ratio, power, and significance set to
3 : 1, 0.9, and 0.05, respectively, and the areas under
the receiver operating characteristic (ROC) curves
(AUCs) of 0.974 (A42/40) and 0.827 (A42) [14].
Unless otherwise stated, results are presented as
means ± standard deviations (SD) or 95% confidence
intervals (CI). CSF A42 and A42/40 cut-offs, and
the corresponding sensitivities and specificities for
PiB PET-positivity, were calculated based on the
dichotomous PET grouping at the maximal Youden
Indices, using a cut-off for PiB positivity of 0.18
[28]. Comparisons of continuous variables were per-
formed with Student’s t-test or Welch test in cases
of unequal variances; dichotomous variables were
compared with chi-squared test. AUCs of the ROC
curves were compared with DeLong test [32]. McNe-
mar’s test for paired proportions was used for testing
differences between the proportions of CSF-PiB con-
cordant cases, and sensitivities and specificities. All
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tests were two-tailed. Logistic regression models
were applied with logit of probability of PET-
positivity (logit (πPET+)) as the outcome, and the
CSF biomarkers and age as continuous, and APOE 4
status (presence of 4 allele = 1) and sex (males = 1)
as dichotomous predictors. Covariates were selected
either for epidemiological reasons (age, sex, APOE)
or due to observed significances between PET+ and
PET- groups (A40 concentrations). Mann-Whitney
U test was used to compare LP/PET intervals between
“CSF/PET concordant” and “CSF/PET discordant”
groups separately for A42 and A42/40. MedCalc
13.1 (MedCalc Software bvba, Ostend, Belgium) and
Stata 14.1 (StatCorp, College Station, TX) were used
for statistical analyses. Significance was defined as
p < 0.05.
RESULTS
Demographic data and CSF biomarkers
As expected given the 3 : 1 (PiB-:PiB+) selection
criterion based on amyloid PET positivity, the cohort
was comprised of 88% cognitively normal (CDR
0) and 12% cognitively abnormal (CDR >0; n = 19
CDR 0.5, n = 3 CDR 1, n = 1 CDR 2) individuals.
The cohort demographics and biomarker data are
shown in Table 1. One sample did not pass QC so
was excluded from statistical analysis. Not unexpect-
edly, the amyloid-positive (PiB+) group was older
than the amyloid-negative (PiB–) group (p < 0.001),
contained a higher percentage of APOE 4 carriers
(p < 0.01), and had a lower mean score on the MMSE
(p = 0.02). The PiB- group contained a greater per-
centage of women than the PiB+ group (65% versus
43%, respectively), but there were no differences in
the years of education (p = 0.28). Median absolute
intervals between the time of CSF collection and PiB
PET scan did not differ significantly between the two
groups (24 versus 33 days, U = 3408, p = 0.45), and in
both groups PET was performed before LP in similar
proportions of the cases (36.7% and 38.7% of PET+
and PET- participants, respectively, χ2(1) = 0.058,
p = 0.81).
Inter-assay CVs, tested with two kit control sam-
ples, were 2.2% and 7.1% for A40, and 2.3% and
6.5% for A42. Median range-to-averages of the
duplicate CSF samples measurements (expressing
intra-assay variation) were 2.3% for A40 and 2.5%
for A42.
By definition, the amount of cortical amyloid depo-
sition (MCBP, mean ± SD) was higher in the PiB+
compared to the PiB– group (p < 0.001). As expected,
PiB+ participants had significantly lower concentra-
tions of CSF A42 (p < 0.001) and a lower mean
A42/40 ratio (p < 0.001), as well as significantly
higher concentrations of CSF Tau (p < 0.001) and
pTau181 (p < 0.001). Interestingly, the PiB+ group
exhibited a modest but significantly higher mean con-
centration of CSF A40 compared to the PiB- group
(p = 0.047). Differences in LP/PET intervals between
“CSF/PET concordant” and “CSF/PET discordant”
groups were not significant (p > 0.1 for both CSF
biomarkers).
Concordance between amyloid PET and CSF
biomarkers
The relationships between CSF analyte values and
cortical amyloid load (PiB MCBP) are shown in
Fig. 1. The optimal CSF cut-offs that best differen-
tiated the dichotomized PiB+ and PiB- groups were
735 pg/mL for A42, 11,600 pg/mL for A40, and
0.05 for the A42/40 ratio. At these cut-offs, the A40,
A42 concentrations and the A42/40 ratio yielded
sensitivities (with dichotomized PiB PET status
defined as the reference) of 85.7% (CI: 72.8–94.1),
Fig. 1. Scatterplots of cortical amyloid PET load using [11C] PiB and concentrations of CSF A42 (A), the A42/40 ratio (B), and A40
(C). Solid vertical line represents the a priori dichotomous cut-off for PiB positivity as published previously [28]. Dashed horizontal lines
on panels A and B represent the best-performing cut-offs of the respective CSF biomarkers calculated in the present study.
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Table 1
Demographic and biomarker data
Characteristic PiB+ PiB– p
N 49 150 NA
Female, % 43% 65% <0.01∗
Age at LP, y 72.4 ± 7.3 64.2 ± 9.6 <0.001
% APOE 4 carriers 58% 31% <0.01∗
Education, y 15.4 ± 2.9 15.9 ± 2.5 0.283
MMSE 28.00 ± 3.03 29.07 ± 1.21 0.02
Median LP-PiB PET interval (IQR), days 24 (16 – 64) 33 (12–94) 0.45†
PiB MCBP 0.5275 ± 0.2454 0.0473 ± 0.0502 <0.001
CSF A40, pg/mL 15 280 ± 4 160 13 890 ± 4 260 0.047
CSF A42, pg/mL 577 ± 184 887 ± 292 <0.001
CSF A42/40 0.038 ± 0.009 0.065 ± 0.013 <0.001
CSF Tau, pg/mL 492 ± 392 234 ± 125 <0.001
CSF pTau181, pg/mL 75.8 ± 35.3 47.2 ± 19.1 <0.001
∗χ2 test. †Mann-Whitney test. APOE, apolipoprotein E; CSF, cerebrospinal fluid; IQR, interquartile range; LP,
lumbar puncture; MCBP, mean cortical binding potential; MMSE, Mini-Mental State Examination (0–30, with 30
a perfect score) at clinical assessment closest in time to LP; NA, not applicable; PET, positron emission tomography;
PiB, Pittsburgh Compound B. Unless otherwise indicated, values represent the mean ± SD.
81.6% (CI: 68.0–91.2) and 95.9% (CI: 86.0–99.5),
respectively, with the corresponding specificities of
34.0% (CI: 26.5–42.2), 72.0% (CI: 64.8–79.6), and
88.0% (CI: 81.7–92.7), corresponding to accuracies
of 46.7% for A40, 74.9% for A42, and 89.4% for
the A42/40 ratio.
For both A42 and A42/40, the percentage of
cases with abnormal CSF findings but normal PET
results (false positives: 20.6% and 9.0% for A42
and A42/40, respectively), clustering in the lower
left quadrant of Fig. 1, was larger than the percent-
age of cases with normal CSF findings and abnormal
PET (false negatives: 4.5% and 1.5% for A42 and
A42/40, respectively), clustering in the upper right
quadrant of Fig. 1. Detailed results are presented in
Table 2.
McNemar test for paired proportions revealed a
highly significantly larger proportion of A42/40-
PET concordant cases compared to A42-PET
concordant cases (χ2(1) = 19.56, p < 0.001), with an
odds ratio of discordant cases of 5.14 (CI: 2.26 to
13.69).
ROC curves yielded AUC’s of 0.599 for A40,
0.814 for A42 and 0.936 for the A42/40 ratio
(Fig. 2), with the A42/40 ratio demonstrating sig-
nificantly higher correspondence with PiB status
compared to the concentrations of A42 (p < 0.001)
and A40 (p < 0.001) (Table 2).
Logistic regression models
Logistic regression models are presented in Sup-
plementary Table 1. In both models (with A42
and A42/40, respectively), when adjusted for A40,
Fig. 2. Receiver operating characteristic (ROC) curves of the CSF
A42 concentration and A42/40 ratio. Values for areas under the
ROC curves (AUC) correspond to mean ± 95% CI. Open circles
represent the combinations of the sensitivities and the specificities
at the maximal Youden Indices.
age, APOE 4 status, and sex, the effects of A42
and A42/40 remained highly significant (p < 0.001).
Consistent with increased A40 in the PiB+ group,
the effect of A40 was positive and significant
(p < 0.001) in the A42 model, but became non-
significant in the A42/40 model (p = 0.36). In both
models, the effects of age were positive and signifi-
cant. Male sex was a positive predictor but only with
borderline significance, and presence of at least one
APOE 4 allele was a non-significant covariate in
both models (p > 0.05).
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Table 2
Analyses of concordance of CSF A42 and the A42/40 ratio with amyloid PET status
Parameter A42 A42/40
Cut-off at the max. YI 735 pg/mL 0.05
Sensitivity at the max. YI (95% CI) 81.6% (68.0–91.2) 95.9% (86.0–99.5)
Specificity at the max. YI (95% CI) 72.7% (64.8–79.6) 88.0% (81.7–92.7)
Positive PV (95% CI) 49.4% (38.1–60.7) 72.3% (59.8–82.7)
Negative PV (95% CI) 92.4% (86.0–96.5) 98.5% (94.7–99.8)
Accuracy (concordance proportion) 74.9% 89.4%∗
%False Pos. (N)/%False Neg. (N) 20.6% (41)/4.5% (9) 9.0% (18)/1.5% (3)
Area Under the ROC curve (95% CI) 0.814 (0.752–0.865) 0.936† (0.892–0.966)
∗p < 0.001 compared to the A42 concentrations (McNemar test for paired proportions); †p < 0.001 compared to the A42 concentra-
tions (DeLong test for differences in AUC’s); False positive, abnormal CSF/normal PET; false negative, normal CSF/abnormal PET; CSF,
cerebrospinal fluid; PET, positron emission tomography; PV, predictive value; ROC, receiver operating characteristic; YI, Youden index.
DISCUSSION
The main finding in this study is significantly bet-
ter concordance of the CSF A42/40 ratio, compared
to CSF A42 alone, with cortical A deposition as
measured by [11C] PiB PET. This finding is consis-
tent with our [14] and others’ [16, 17] reports of better
diagnostic accuracy of the A42/40 ratio compared
to A42 in early AD, as well as with CSF biomark-
ers of neurodegeneration, Tau and pTau181 [13]. We
hypothesize that the concentration of A42 in the CSF
depends not only on the physiological amyloid status
of a given individual (presence or absence of amy-
loid pathology) but also on the total amount of A
peptides that are present. By normalizing to the con-
centration of A40, the most abundant A species in
the CSF, the ratio removes the potential confound of
differences in overall A concentration and provides
a better index of underlying amyloid-related pathol-
ogy. Two experimental observations further support
the application of the A42/40 ratio for AD diag-
nostics: (a) A42/40 is less prone to the error of
misinterpretation when non-polypropylene test tubes
(as are often found in standard clinical LP trays) are
used to collect CSF [18] likely due to the fact that both
A isoforms seem to absorb to the tube surface to a
similar extent; and (b) two studies using a different
set of ELISAs (produced by a currently non-existing
vendor and based on N-terminally non-specific anti-
bodies) that have applied the A42/40 ratio to predict
AD in MCI subjects [15] and discriminate early
symptomatic AD from controls [19] reported almost
identical A42/40 cut-offs (0.095 and 0.098, respec-
tively), whereas the corresponding cut-offs for A42
alone differed by more than 15% (640 pg/mL and
550 pg/mL, respectively).
The analyses of CSF A isoforms in the current
study were performed with two novel assays that
were validated recently by our group and approved for
human in vitro diagnostic (IVD) use in Europe [14].
The assays exhibit very good analytical performance,
both apply the same protocol for sample dilution,
incubation, and washing steps, and require only a
small volume (25L) of CSF for both biomarkers
measured in duplicate. Interestingly, we observed
small but significantly (p = 0.047) elevated levels of
CSF A40 in the PiB+ group compared to the PiB-
group. This is consistent with similarly slight, but
significant, increases observed in the MCI/AD group
compared to controls when measured with the same
assay [14]. Also, in a recent study by Dorey et al.
[33] investigating the performance of these mark-
ers for correspondence with clinical diagnosis, CSF
A40 concentrations were higher in AD than non-AD
patients, and inclusion of CSF A40 as an A42/40
ratio corrected 76.2% of misinterpreted cases in AD
patients with normal CSF A42 concentrations and
94.7% of cases when A40 was used alone. When
we adjusted for the A42/40 ratio, but not for A42
alone, the A40 concentration became insignificant
as a predictor of amyloid PET status in the logis-
tic regression models, whereas both A42 and the
A42/40 ratio remained highly significant as predic-
tors of amyloid PET after adjustment for A40, age,
APOE4 carriage, and sex. After adjustment for other
covariates, older age remained a significant predictor
of cortical amyloid-PET positivity, consistent with
age being the strongest risk factor for AD. Odds ratio
of A42-PET versus A42/40-PET discordant cases,
resulting from McNemar test, indicates that the odds
to falsely predict the PET outcome is five-fold lower
with the A42/40 ratio compared to A42 alone.
Both biomarker modalities (CSF analysis and
amyloid PET) have their practical advantages and dis-
advantages in terms of cost (actual and reimbursable),
perceived invasiveness, and availability in clinical as
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well as research settings [34], and our results do not
endorse one or the other as a “gold standard” for amy-
loid biomarker positivity. From a scientific point of
view, the discordance between CSF A42 and amy-
loid PET (typically observed as false positives, i.e.,
abnormal/low CSF A42 in the absence of amyloid-
PET positivity) has been hypothesized to be due to
possible methodological variability/limitations in the
CSF assays, differences in the temporal trajectories of
processes identified by the two biomarker modalities
(e.g., CSF levels of soluble A42 becoming abnor-
mal prior to aggregated A42 [amyloid] becoming
detectable by PET), and/or inter-individual differ-
ences in overall levels of A peptides [9, 12]. These
possible scenarios are not mutually exclusive. Our
use of well-performing assays that utilize the same
dilution factor for both A42 and A40 minimizes
methodological variability as a source of discordance
between CSF A42 and amyloid PET results and
increases the confidence of the ratio as being an accu-
rate measure of the proportion of each of these species
in CSF. In so doing, the increase in concordance that
we observe for the A42/40 ratio suggests much of
the “false positives” as defined by CSF A42 is due
to lower overall levels of A in these individuals,
whereas the “false negatives” can be attributed in
large part to higher overall CSF A levels. Indeed,
the negative predictive value of the A42/40 ratio
in this study (98%) approached 100%, thus support-
ing its use for ruling out the presence of underlying
amyloid pathology. While use of the ratio also sig-
nificantly increased the positive predictive value for
cortical amyloid PET positivity, 9% of individuals in
this cohort were still classified as amyloid-positive
by CSF A42/40 but amyloid-negative by PET (false
negative), consistent with CSF A42 levels drop-
ping prior to cortical amyloid being detectable by
PiB PET. That all but one participant in this discor-
dant group (whether CSF abnormality was defined
by A42 alone or the A42/40 ratio) were cognitively
normal is consistent with findings from a recent study
in which low CSF A42 but normal amyloid PET
was much more frequent in cognitively normal indi-
viduals and early MCI cases than in the late MCI
stage or AD dementia [12]. Longitudinal CSF and
amyloid PET biomarker evaluation will be required
to test whether levels of CSF A42 indeed become
abnormal (drop) before amyloid-positivity is detected
with PET as has been suggested by a recent study by
Vlassenko and colleagues [30]. That study, however,
did not assess CSF A40 so comparison of the two
CSF measures was not possible. Results of a recent
study by Palmqvist et al. also suggest that decreases in
CSF A42 precede alterations in amyloid PET [35].
Interestingly, another recent study using different
ELISAs also reported better correspondence of the
A42/40 ratio with A PET, however, with a higher
proportion of A–/PET+ individuals compared to the
present study [36]. This discrepancy is likely due
to the differences in the cohorts (higher numbers of
cognitively normal individuals expected to be in the
preclinical period in the current cohort) and/or dif-
ferent methodological issues. Another study reported
no significant differences in concordances between
A42/40 and A42 with amyloid PET, although the
AUC for A42/40 was slightly larger than that for
A42 alone [37]. This lack of significance might
be attributed to the lower statistical power (a much
smaller cohort, n = 38) and/or the use of different
ELISAs and PET tracer (18F-flutemetamol) in that
study. Similarly, another smaller study concluded that
the A42/40 ratio had a “large” effect size (defined as
Cohen’s f2 = 0.35), compared to a “medium” effect
size (defined as Cohen’s f2 = 0.15), for A42, in pre-
dicting concurrent PiB burden [38]. Aggregation of
soluble A into diffuse, non-fibrillar plaques that are
not identifiable by amyloid PET imaging may also
contribute to the “false negative” discordant cases
[39]. If confirmed, a finding of CSF alterations pre-
ceding those in PET would support the CSF A42/40
ratio (and perhaps even A42 alone, albeit with less
accuracy) as the earliest detectable marker of -
amyloidosis.
Our study is not without limitations. Although
amyloid PET in this study is considered to be the ref-
erence to define the presence of amyloid, positivity
was defined according to dichotomous, research-
based thresholds in a defined set of cortical regions.
Also, since samples were specifically selected to
over-represent possible CSF/PET discordance (by
evaluating 25% PET-positive and 75% PET-negative
cases), the cohort does not reflect the general dis-
tribution of amyloid PET positivity in the general
population. Furthermore, because of this strategy, the
cohort was significantly skewed toward cognitively
normal individuals (88% cognitively normal, 12%
cognitively abnormal). Additional study is needed in
larger cohorts comprised of greater numbers of cogni-
tively abnormal individuals, as well as those clinically
diagnosed with non-AD dementias in order to better
evaluate the CSF/PET concordance in non-AD pop-
ulations. Finally, we performed statistical analyses of
concordance after calculating optimal cut-off values
for both CSF biomarkers. As this was designed to be a
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biomarker concordance study, independent of clinical
status, the diagnostic value of any of the biomarkers
and modalities studied here remains to be evaluated.
In summary, the CSF A42/40 ratio performs bet-
ter, compared to CSF A42 alone, in identifying
individuals with versus without underlying cortical
amyloid as defined by PiB PET. The ratio outperforms
the single A42 measure in all metrics, including
sensitivity, specificity, positive and negative predic-
tive values, and overall accuracy. Of special note
is its better concordance in individuals classified as
amyloid-negative by PET, suggesting that the higher
discordance between CSF A42 alone and amyloid
PET-positivity may reflect overall lower levels of
A42 in some individuals as opposed to its aggrega-
tion into plaques (or oligomeric forms that are likely
not detected with the current assays [40]. The CSF
A42/40 ratio may, therefore, be useful as a proxy for
amyloid status in AD clinical trials and eventually in
clinical care settings.
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